Transdermal Drug Delivery Videos

  1. Relying On Human Factors Clinical Data For Regulatory Approvals 2/17/2026

    In this segment of the Drug Delivery Leader Live online event, Injected, Infused, or Implanted: A Penetrating Look At Patient Centricity, Chief Editor Tom von Gunden relays an audience question about increased FDA regulatory scrutiny around human factors. Panelists Jonathan Amaya-Hodes and Shannon Hoste comment on the importance of clinical data in regulatory submissions and in approval pathways. 

  2. Broadening The Range Of Self-Administered Biologics With Stevanato Group's Riccardo Butta 1/20/2025

    Along with the goal of moving a wider range of biologics-based therapies into self-administered, in-home scenarios comes the challenge of delivering increased dosage volumes and higher viscosities via subcutaneous and transdermal methods. In this episode of Supplier Horizons, host Tom von Gunden talks with Stevanato Group’s President, Americas, Riccardo Butta about the convergence of human factors and device design during platform development for injectable and on-body delivery systems.

  3. Leveraging Combination Therapies For Precision Targeting 10/8/2025

    In this segment of the Drug Delivery Leader Live online event, Next-Gen Drug Delivery: Rethinking Routes For New Therapies, Carolyn Dorgan, director of technical services at device design consultancy Suttons Creek, highlights the promise of using combination products and combination therapies to reach difficult targets with precision. Carolyn notes crossing the blood-brain barrier as an example of a key therapy delivery advance. 

  4. Applying Clinical Data And Process Controls In Biologics Development 4/13/2026

    In this segment of the Drug Delivery Leader Live online event, Large Molecule Biologics Delivery: Aligning Formulations, Doses, And Devices, Chief Editor Tom von Gunden asks panelist Rubi Burlage about key considerations as a biologics-based product moves into later clinical stages and on toward commercial scale-up. Burlage highlights control strategy, clinical data, human factors studies, and supply chain as areas calling for significant attention during later-stage development. 

  5. Preparing For Combination Product Regulatory Inspections 4/11/2025

    In this episode of The Combination Products Handbook: The Series, host Tom von Gunden discusses Chapter 9 of The Combination Products Handbook: A Practical Guide for Combination Products and Other Combined Use Systems (CRC Press) with the book’s editor, Susan Neadle, and chapter co-author Kim Trautman.

  6. Becoming A Combination Product Development Organization 1/12/2026

    In this segment of the Drug Delivery Leader Live online event, Eying The Drug Delivery Regulatory Landscape: The 'Must See' Watch List For 2026, Chief Editor Tom von Gunden asks the panel to comment on regulatory challenges and considerations for traditional drug product pharma companies moving into combination product development. Patient centricity, device expertise, and supplier relationships are among the topics identified.

  7. Partnering On Patient Needs With DSM-Firmenich's George Mihov And Lukasz Koroniak 10/23/2024

    Principal Scientist George Mihov and Global Biomaterials Director Lukasz Koroniak from DSM-Firmenich join Supplier Horizons host Tom von Gunden to discuss partnering with pharma on formulation development. Among the topics covered are translational research, materials development, and complex molecules required for biologic-based therapies.

  8. What Is There to Learn from a Combination Products Handbook? Plenty! 10/15/2024

    In this initial episode of The Combination Products Handbook: The Series, a chapter-by chapter videocast series introducing topics from The Combination Products Handbook: A Practical Guide for Combination Products and Other Combined Use Systems (CRC Press, 2023), host Tom von Gunden discusses the book’s intent with its editor, Susan Neadle. The discussion focuses on the rationale for each chapter and the expert contributions of various chapter authors and co-authors.

  9. Considering Injection Options For High Dose Biologics 4/13/2026

    In this segment of the Drug Delivery Leader Live online event, Large Molecule Biologics Delivery: Aligning Formulations, Doses, And Devices, Chief Editor Tom von Gunden directs to panelist Dominick DeGrazio an audience question about wearable devices versus autoinjectors for frequent dosing of biologics. DeGrazio describes key factors in the decision including dose volume, injection rate, and patient preference and compliance. 

  10. The Regulatory Intent Of A URRA For Combination Products 12/11/2024

    To what extent are approaches to conducting risk assessments specified in the FDA URRA (Use-Related Risk Analysis) guidance? In this segment of the Drug Delivery Leader Live event Human Factors Risk Analysis: Leveraging URRA And UFMEA Tools, Shannon Hoste, chief scientific officer at Pathway for Patient Health, offers context-setting perspective on what FDA is looking for when reviewing URRA compliance.